Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Respiratory Distress Syndrome · Cardiogenic Shock · WINT

WINDTREE THERAPEUTICS INC

WINDTREE THERAPEUTICS INC /DE/

WINDTREE THERAPEUTICS INC clinical programs — 13 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
2600 Kelly Rd., Suite 100, Warrington, PA 18976, US HQ
1992 Founded
17 Employees
Public company Type
WINT · NYSE Ticker
Company details
Status
Public
HQ
2600 Kelly Rd., Suite 100, Warrington, PA 18976, US
Founded
1992
Employees
17
Programs
15
Drugs
9
Patents
4
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

WINDTREE THERAPEUTICS INC projects

13 ClinicalTrials.gov programs sponsored by WINDTREE THERAPEUTICS INC.

WINDTREE THERAPEUTICS INC has 13 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

13 programs

Clinical programs

  1. A.1 Lucinactant

    WINDTREE THERAPEUTICS INC /DE/

    Acute Respiratory Distress Syndrome

    phase 2 small molecule terminated

    1 trial

  2. Aerosolized lucinactant

    WINDTREE THERAPEUTICS INC /DE/

    Respiratory Distress Syndrome

    phase 2 small molecule terminated

    1 trial

  3. Istaroxime

    WINDTREE THERAPEUTICS INC /DE/

    Cardiogenic Shock

    phase 2 small molecule active

    2 trials

  4. Istaroxime, LActose

    WINDTREE THERAPEUTICS INC /DE/

    Cardiogenic Shock

    phase 2 small molecule active

    1 trial

  5. Lucinactant

    WINDTREE THERAPEUTICS INC /DE/

    COVID-19

    phase 2 small molecule completed

    1 trial

  6. Lucinactant

    WINDTREE THERAPEUTICS INC /DE/

    Acute Hypoxemic Respiratory Failure

    phase 2 small molecule completed

    1 trial

  7. Lucinactant 175 mg/kg

    WINDTREE THERAPEUTICS INC /DE/

    Respiratory Distress Syndrome, Newborn

    phase 2 small molecule terminated

    1 trial

  8. Lucinactant delivered via investigational delivery device

    WINDTREE THERAPEUTICS INC /DE/

    Respiratory Distress Syndrome

    phase 2 small molecule completed

    1 trial

  9. Lucinactant first

    WINDTREE THERAPEUTICS INC /DE/

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  10. Lucinactant for Inhalation

    WINDTREE THERAPEUTICS INC /DE/

    Respiratory Distress Syndrome, Newborn

    phase 2 other terminated

    1 trial

  11. Lucinactant for inhalation

    WINDTREE THERAPEUTICS INC /DE/

    Respiratory Distress Syndrome

    phase 2 other terminated

    2 trials

  12. Placebo

    WINDTREE THERAPEUTICS INC /DE/

    Acute Decompensated Heart Failure

    phase 2 small molecule completed

    1 trial

  13. Rostafuroxin

    WINDTREE THERAPEUTICS INC /DE/

    Hypertension

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does WINDTREE THERAPEUTICS INC have?

13 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.